Developer docs
API playgroundTry for free, no card

Search company profiles

Axonics Modulation Technologies

Full company profile

uuid00044k3

Namestring
Axonics Modulation Technologies
Legal namestring
Axonics Inc.
Websiteurl
axonics.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Axonics Modulation Technologies is a medical device company founded in 2012 and headquartered in Irvine, California, specializing in the development and commercialization of implantable sacral neuromodulation (SNM) devices for the treatment of pelvic floor disorders. The company's core products target patients with chronic overactive bladder, urinary incontinence, fecal incontinence, and urinary retention who have failed conservative therapies such as medication and behavioral interventions. Axonics' proprietary technology delivers controlled electrical stimulation to the sacral nerve via an implanted pulse generator, leads, and remote control accessories, addressing a clinical niche within the broader neuromodulation space.

The company's business model is built on hardware sales of implantable SNM systems to hospitals, specialty clinics, and urology/urogynecology practices through a direct enterprise field sales force. Revenue is generated through initial device implantation procedures plus recurring sales of replacement components and accessories over multi-year device lifecycles. Axonics targeted medical specialists—primarily urologists, urogynecologists, and colorectal surgeons—who serve as both clinical decision-makers and implanting physicians. Marketing channels included medical conferences, peer-to-peer physician education, and clinical publications to drive adoption among key opinion leaders.

Following its initial public offering on NASDAQ under ticker AXNX, Axonics scaled commercially and executed the 2021 acquisition of Contura for approximately $200 million to expand its neuromodulation portfolio. In November 2024, Boston Scientific completed its acquisition of Axonics for approximately $6.0 billion, integrating the company's SNM technology and pelvic floor health products into Boston Scientific's Neuromodulation segment, which subsequently reported 15% organic sales growth with explicit contributions from the Axonics business.

Short descriptiontext

Axonics Modulation Technologies, founded in 2012 and headquartered in Irvine, California, developed and commercialized implantable sacral neuromodulation devices for treating overactive bladder, urinary incontinence, and fecal incontinence, serving urologists and urogynecologists via direct hospital sales. Acquired by Boston Scientific in November 2024 for approximately $6.0 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sacral neuromodulation devices, implantable medical devices, pelvic floor disorder treatment, sacral nerve stimulation, neuromodulation therapy systems
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Sacral Neuromodulation Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Implantable Neuromodulation Devices
TypeHardware Sales
Description

Sale of sacral neuromodulation implantable devices for treating pelvic floor disorders. Revenue generated from device sales to hospitals and specialty clinics for implantation procedures.

dimensionmarketresearch.com
2Device Accessories and Replacements
TypeHardware Sales
Description

Revenue from accessories, replacement components, and ongoing patient follow-up products associated with the implanted neuromodulation systems.

openpr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Axonics Modulation Technologies develops and manufactures implantable sacral neuromodulation (SNM) devices that deliver electrical stimulation to the sacral nerve to treat overactive bladder, urinary incontinence, and fecal incontinence. The company also sells accessories, replacement components, and patient follow-up products associated with its implanted neuromodulation systems.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Sacral Neuromodulation (SNM) Implantable Devices
CategorySacral Neuromodulation Devices
2Device Accessories and Replacements
CategorySacral Neuromodulation Devices
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Boston Scientific completed the acquisition of Axonics Inc. in November 2024, integrating Axonics' sacral neuromodulation technology and pelvic floor health products into Boston Scientific's broader neuromodulation and pelvic health portfolio. The acquisition strengthened Boston Scientific's position as a key player in the pelvic floor health technology market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medtronic markets InterStim, the leading sacral neuromodulation system for overactive bladder and incontinence, and is the dominant direct competitor to Axonics in the same SNM therapy category and same physician call point (urology/urogynecology).

TypeBroad incumbent
Description

Parent company of Axonics following the November 2024 acquisition and a broad incumbent in neuromodulation (spinal cord stimulation, deep brain stimulation) and pelvic health; operates a wider portfolio that overlaps with Axonics' SNM franchise.

TypeBroad incumbent
Description

Abbott's Neuromodulation business (Proclaim family) operates in implantable neurostimulation (spinal cord and dorsal root ganglion stimulation) for chronic pain, overlapping broadly with the neuromodulation category Axonics operates in.

TypeDirect peer
Description

Nevro develops implantable spinal cord stimulation (HF10 therapy) systems for chronic pain, making it a direct peer in the implantable neuromodulation device category targeting physician specialists.

TypeDirect peer
Description

Inspire markets an implantable neurostimulation device for obstructive sleep apnea, making it a direct peer in the implantable neuromodulation device category targeting specialist physicians and hospital implanters.

TypeEmerging player
Description

Nuvectra developed the Algovita spinal cord stimulation system, an emerging player in implantable neuromodulation with partial overlap with Axonics in the broader neurostim device category.

TypeDirect peer
Description

Laborie is a urology and pelvic health device company whose portfolio overlaps with Axonics' end market (urologists treating incontinence and pelvic floor disorders), making it a peer along the same physician call point.

8Cogentix Medical (now part of Laborie)
TypeEmerging player
Description

Cogentix (now under Laborie) develops urology devices including Urgent PC percutaneous tibial nerve stimulation (PTNS), a non-implantable alternative therapy competing for the same refractory OAB patient population Axonics serves.

TypeEmerging player
Description

Stimwave developed miniaturized, wirelessly powered peripheral nerve stimulation systems, representing an emerging neurostimulation peer with overlapping technology and therapeutic positioning.

TypeBroad incumbent
Description

Coloplast is a major player in continence care and pelvic health products (catheters, slings, bowel management), addressing the same patient population and physician call point as Axonics through adjacent, non-implant therapies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Axonics Modulation Technologies

Sacral Neuromodulation Devicesaxonics.com

Axonics Modulation Technologies, founded in 2012 and headquartered in Irvine, California, developed and commercialized implantable sacral neuromodulation devices for treating overactive bladder, urinary incontinence, and fecal incontinence, serving urologists and urogynecologists via direct hospital sales. Acquired by Boston Scientific in November 2024 for approximately $6.0 billion.

What Axonics Modulation Technologies does

Axonics Modulation Technologies is a medical device company founded in 2012 and headquartered in Irvine, California, specializing in the development and commercialization of implantable sacral neuromodulation (SNM) devices for the treatment of pelvic floor disorders. The company's core products target patients with chronic overactive bladder, urinary incontinence, fecal incontinence, and urinary retention who have failed conservative therapies such as medication and behavioral interventions. Axonics' proprietary technology delivers controlled electrical stimulation to the sacral nerve via an implanted pulse generator, leads, and remote control accessories, addressing a clinical niche within the broader neuromodulation space.

The company's business model is built on hardware sales of implantable SNM systems to hospitals, specialty clinics, and urology/urogynecology practices through a direct enterprise field sales force. Revenue is generated through initial device implantation procedures plus recurring sales of replacement components and accessories over multi-year device lifecycles. Axonics targeted medical specialists—primarily urologists, urogynecologists, and colorectal surgeons—who serve as both clinical decision-makers and implanting physicians. Marketing channels included medical conferences, peer-to-peer physician education, and clinical publications to drive adoption among key opinion leaders.

Following its initial public offering on NASDAQ under ticker AXNX, Axonics scaled commercially and executed the 2021 acquisition of Contura for approximately $200 million to expand its neuromodulation portfolio. In November 2024, Boston Scientific completed its acquisition of Axonics for approximately $6.0 billion, integrating the company's SNM technology and pelvic floor health products into Boston Scientific's Neuromodulation segment, which subsequently reported 15% organic sales growth with explicit contributions from the Axonics business.

Axonics Modulation Technologies firmographics

Firmographics
Name
Axonics Modulation Technologies
Legal name
Axonics Inc.
Website
https://axonics.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
251–500 employees
Short description
Axonics Modulation Technologies, founded in 2012 and headquartered in Irvine, California, developed and commercialized implantable sacral neuromodulation devices for treating overactive bladder, urinary incontinence, and fecal incontinence, serving urologists and urogynecologists via direct hospital sales. Acquired by Boston Scientific in November 2024 for approximately $6.0 billion.
Ownership category
akta.pro rank

Axonics Modulation Technologies industry classification

Industry
Product category
Sacral Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Sacral neuromodulation devices
  • Implantable medical devices
  • Pelvic floor disorder treatment
  • Sacral nerve stimulation
  • Neuromodulation therapy systems

Where Axonics Modulation Technologies is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Axonics Modulation Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Implantable Neuromodulation Devices: Sale of sacral neuromodulation implantable devices for treating pelvic floor disorders. Revenue generated from device sales to hospitals and specialty clinics for implantation procedures.
  2. Device Accessories and Replacements: Revenue from accessories, replacement components, and ongoing patient follow-up products associated with the implanted neuromodulation systems.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Axonics Modulation Technologies product offering

Product offering

Core offering

Axonics Modulation Technologies develops and manufactures implantable sacral neuromodulation (SNM) devices that deliver electrical stimulation to the sacral nerve to treat overactive bladder, urinary incontinence, and fecal incontinence. The company also sells accessories, replacement components, and patient follow-up products associated with its implanted neuromodulation systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sacral Neuromodulation (SNM) Implantable Devices
  • Device Accessories and Replacements

Companies that use Axonics Modulation Technologies

Customer profile

Segments3 records

Ideal customer profiles2 records

Axonics Modulation Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Axonics Modulation Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Boston Scientific CorporationflagshipStrategic or Co-development Partner · 1 November 2024Boston Scientific completed the acquisition of Axonics Inc. in November 2024, integrating Axonics' sacral neuromodulation technology and pelvic floor health products into Boston Scientific's broader neuromodulation and pelvic health portfolio. The acquisition strengthened Boston Scientific's position as a key player in the pelvic floor health technology market.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Axonics Modulation Technologies competitors and assessment

Company assessment

Direct peers

  • Medtronic: Medtronic markets InterStim, the leading sacral neuromodulation system for overactive bladder and incontinence, and is the dominant direct competitor to Axonics in the same SNM therapy category and same physician call point (urology/urogynecology).
  • Nevro Corp: Nevro develops implantable spinal cord stimulation (HF10 therapy) systems for chronic pain, making it a direct peer in the implantable neuromodulation device category targeting physician specialists.
  • Inspire Medical Systems: Inspire markets an implantable neurostimulation device for obstructive sleep apnea, making it a direct peer in the implantable neuromodulation device category targeting specialist physicians and hospital implanters.
  • Laborie Medical Technologies: Laborie is a urology and pelvic health device company whose portfolio overlaps with Axonics' end market (urologists treating incontinence and pelvic floor disorders), making it a peer along the same physician call point.

Broad incumbents

  • Boston Scientific Corporation: Parent company of Axonics following the November 2024 acquisition and a broad incumbent in neuromodulation (spinal cord stimulation, deep brain stimulation) and pelvic health; operates a wider portfolio that overlaps with Axonics' SNM franchise.
  • Abbott: Abbott's Neuromodulation business (Proclaim family) operates in implantable neurostimulation (spinal cord and dorsal root ganglion stimulation) for chronic pain, overlapping broadly with the neuromodulation category Axonics operates in.
  • Coloplast: Coloplast is a major player in continence care and pelvic health products (catheters, slings, bowel management), addressing the same patient population and physician call point as Axonics through adjacent, non-implant therapies.

Emerging players

  • Nuvectra: Nuvectra developed the Algovita spinal cord stimulation system, an emerging player in implantable neuromodulation with partial overlap with Axonics in the broader neurostim device category.
  • Cogentix Medical (now part of Laborie): Cogentix (now under Laborie) develops urology devices including Urgent PC percutaneous tibial nerve stimulation (PTNS), a non-implantable alternative therapy competing for the same refractory OAB patient population Axonics serves.
  • Stimwave Technologies: Stimwave developed miniaturized, wirelessly powered peripheral nerve stimulation systems, representing an emerging neurostimulation peer with overlapping technology and therapeutic positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Axonics Modulation Technologies social profiles

Digital presence

Axonics Modulation Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Axonics Modulation Technologies leadership team

Management profile

Number of profiles

Profiles6 records

Axonics Modulation Technologies funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Axonics Modulation Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axonics Modulation Technologies

What does Axonics Modulation Technologies do?

Axonics Modulation Technologies develops and manufactures implantable sacral neuromodulation (SNM) devices that deliver electrical stimulation to the sacral nerve to treat overactive bladder, urinary incontinence, and fecal incontinence. The company also sells accessories, replacement components, and patient follow-up products associated with its implanted neuromodulation systems.

Is Axonics Modulation Technologies a public or private company?

Axonics Modulation Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Axonics Modulation Technologies founded?

Axonics Modulation Technologies was founded in 2012. It employs 251 to 500 people.

Where is Axonics Modulation Technologies based?

Axonics Modulation Technologies is headquartered in Irvine, United States, in the North America region.

How does Axonics Modulation Technologies make money?

Two revenue lines are on record. Implantable Neuromodulation Devices are the primary driver. The others are device Accessories and Replacements.

Who are Axonics Modulation Technologies's main competitors?

Direct peers on record are Medtronic, Nevro Corp, Inspire Medical Systems and Laborie Medical Technologies. Broad incumbents are Boston Scientific Corporation, Abbott and Coloplast. Emerging players are Nuvectra, Cogentix Medical (now part of Laborie) and Stimwave Technologies.

Does Axonics Modulation Technologies have an API?

No public API is recorded for Axonics Modulation Technologies.

What industry is Axonics Modulation Technologies in?

Axonics Modulation Technologies's product category is Sacral Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Urology TimesNew recharge-free sacral neuromodulation system for bladder/bowel dysfunction launches in USAxonics Inc. launched the Axonics F15 recharge-free sacral neuromodulation system in the US for bladder and bowel dysfunction. The device uses a primary cell battery, offers 15+ years of function at standard settings, and is MRI-compatible. Axonics CEO Raymond W. Cohen said physician response has been overwhelmingly positive.Urology TimesDr. Syan on new recharge-free sacral neuromodulation system for bladder/bowel dysfunctionDr. Raveen Syan discusses Axonics F15, an FDA-approved recharge-free sacral neuromodulation implantable neurostimulator for bladder and bowel dysfunction. The video features Syan, an assistant professor of Clinical Urology at the University of Miami Miller School of Medicine.Medical Device NetworkFDA clears Bright Uro’s abdominal sensor for evaluating bladder dysfunctionThe FDA cleared Bright Uro's abdominal sensor, adding multi-channel urodynamic and pressure studies to its Glean urodynamics system for bladder dysfunction. The clearance enables catheter-free ambulatory urodynamics for lower urinary tract dysfunction, with an estimated 80 million US patients affected.EIN PresswireHysteroscopy Instruments Market Size to Exceed USD 3.45 Billion by 2032 with AI and Office-Based ShiftThe hysteroscopy instruments market is projected to grow from USD 1.98 billion in 2025 to USD 3.45 billion by 2032, a CAGR of 7.2%. Office-based procedures are the fastest-growing application, and AI-integrated systems are expected to become standard care.PR NewswireE2 (Endovascular Engineering, Inc.) Appoints Justin Farry as Chief Financial Officer to Support Next Phase of GrowthE2 (Endovascular Engineering, Inc.) announced the appointment of Justin Farry as its new Chief Financial Officer, effective immediately. Farry brings 25+ years of MedTech experience, most recently serving as VP of Financial Planning & Analysis at Axonics, Inc., which scaled to over $400 million in trailing-twelve-month revenue before being acquired by Boston Scientific for $3.7 billion in 2024. The appointment is intended to support E2's preparation for the commercialization of its Hēlo™ Thrombectomy System for the treatment of venous thromboembolism.ClarivateUnited States neurostimulation device marketThe US neurostimulation device market is projected to grow through 2033, driven by continuous product innovation and strategic acquisitions such as Boston Scientific's purchase of Axonics. This growth is expected to be partially offset by the availability of alternative noninvasive treatments and strict reimbursement requirements.TracxnTop Companies in Gastrointestinal Devices (Jul, 2025)The article presents a ranking of top startups in the gastrointestinal devices sector, highlighting companies such as Axonics, Sequana Medical, Creo Medical, and Apollo Endo. It details their founding years, locations, funding stages, and specific medical technologies developed for urinary, bowel, and obesity treatments. The text also notes that an average of five new companies in this field have been launched annually over the past decade.Neurotechreports2024 neurotechnology industry events, Axonics, Boston Scientific, Medtronic, mergers acquisitions (M&A) venture capital funding rounds, Shai Gozani, Pixium Vision, Tether, CMS codesIn 2024, Boston Scientific completed a significant acquisition of Axonics for $3.7 billion, highlighting optimism in the neurotechnology industry. This acquisition has potentially stimulated further investment, as evidenced by recent funding rounds totaling over $300 million across various neurotech firms. Overall, the year showed more positive than negative developments in the sector, setting a hopeful tone for 2025.Castle PlacementTop 10 HealthCare Devices and Supplies Capital Raises in the U.S.A market roundup covering November 1-15, 2024, lists ten capital-raising transactions in U.S. healthcare devices and supplies, including PE growth, M&A and venture rounds. Highlights include Axonics' $3.62 billion acquisition by Boston Scientific, Beta Bionics' $60 million Series E round led by Wellington Management, and Inmedix' $720,000 seed round.PR NewswireBoston Scientific Closes Acquisition of Axonics, Inc.Boston Scientific closed its acquisition of Axonics, a medical technology company focused on urinary and bowel dysfunction devices. The deal was priced at $71 cash per share, with an equity value of $3.7 billion and enterprise value of $3.3 billion. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter.